Caribou Biosciences (CRBU) Net Cash Flow (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Net Cash Flow of -$303000.0 for Q1 2026, down 102.31% year-over-year from $13.1 million in Q1 2025, and down 124.28% quarter-over-quarter from $1.2 million in Q4 2025.
Caribou Biosciences (CRBU) Net Cash Flow (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Net Cash Flow for 7 consecutive years, with -$303000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 102.31% year-over-year to -$303000.0; the TTM figure through Mar 2026 stood at -$17.4 million (up 13.13% YoY), while the FY2025 annual figure was -$3.9 million, up 88.72% from the prior year.
- Net Cash Flow eased to -$303000.0 in Q1 2026 per CRBU's latest filing, from $1.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $37.9 million in Q3 2023 and bottomed at -$92.8 million in Q1 2022.
- Historically, Net Cash Flow has averaged -$13.4 million across 5 years, with a median of -$5.9 million in 2024.
- Annual changes were most pronounced in 2024 — Net Cash Flow tumbled 185.75% — and 2025, when it surged 844.84%.
- Caribou Biosciences' Net Cash Flow stood at -$23.7 million in 2022, then plunged by 122.75% to -$52.9 million in 2023, then surged by 70.36% to -$15.7 million in 2024, then surged by 107.96% to $1.2 million in 2025, then slumped by 124.28% to -$303000.0 in 2026.
- Business Quant data shows CRBU's Net Cash Flow at -$303000.0 in Q1 2026, $1.2 million in Q4 2025, and -$14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 14.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.08 Mn |
| Jun 30, 2026 | 14.08 Mn |
| Mar 31, 2026 | -303,000.00 |
| Mar 31, 2026 | -303,000.00 |
| Dec 31, 2025 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | -14.09 Mn |
| Sep 30, 2025 | -14.09 Mn |
| Jun 30, 2025 | -4.22 Mn |
| Jun 30, 2025 | -4.22 Mn |
| Mar 31, 2025 | 13.12 Mn |
| Mar 31, 2025 | 13.12 Mn |
| Dec 31, 2024 | -15.68 Mn |
| Dec 31, 2024 | -15.68 Mn |
| Sep 30, 2024 | -5.90 Mn |
| Sep 30, 2024 | -5.90 Mn |
| Jun 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -11.53 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Mar 31, 2024 | -1.76 Mn |